...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Churg and Strauss vasculitis in the course of masitinib treatment: a first report.
【24h】

Churg and Strauss vasculitis in the course of masitinib treatment: a first report.

机译：马赛替尼治疗过程中的Churg和Strauss血管炎：首次报道。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Masitinib mesylate (AB1010), a novel tyrosine kinase inhibitor with high selec- tivity for c-kit and PDGF receptors, and to a lesser extent to Lyn received a great deal of attention as therapeutic targets for pulmonary and inflammatory diseases (1, 2). We discuss the case of a Churg and Strauss syndrome (CSS) occurring during this treatment. A 55-year-old man, nonsmoker, was treated for asthma since the age of 35 years, with nasal polyposis and aspirin intolerance. The asthma became poorly controlled (FEV,: 33-49% predicted) in his fourth decade despite inhaled steroids plus long-acting beta2 mimetics, montelukast and oral predni-sone (20 mg/day). The patient was enrolled onto a phase 2 clinical trial with masitinib (1) which allowed a discontinuation of steroids within the first 3 months because of an improvement of asthma (FEV_1: 68% predicted). Soon after, the patient presented a purpuric dermatosis on lower limbs and right arm related to superficial vasculitis that disappeared after a short course of steroids.
机译：甲磺酸马赛替尼（AB1010）是一种新型酪氨酸激酶抑制剂，对c-kit和PDGF受体具有较高的选择性，而在较小程度上对Lyn而言，作为治疗肺和炎性疾病的靶点受到了广泛关注（1、2） 。我们讨论在这种治疗过程中发生的Churg和Strauss综合征（CSS）的情况。一名55岁的不吸烟者自35岁以来就接受了哮喘治疗，鼻息肉病和阿司匹林不耐受。尽管吸入类固醇加长效β2模拟物，孟鲁司特和口服泼尼松（20毫克/天），但哮喘病在其第四个十年的控制能力很差（FEV：预测值为33-49％）。该患者参加了masitinib（1）的2期临床试验，该试验由于哮喘的改善允许在头3个月内停用类固醇（FEV_1：预计为68％）。此后不久，患者出现与浅表性血管炎有关的下肢和右臂紫癜性皮肤病，经短暂的类固醇治疗后消失。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号